{"id":"https://openalex.org/W2289934799","doi":"https://doi.org/10.1080/08897077.2015.1133472","title":"Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety","display_name":"Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety","alternate_titles":[],"publication_year":2016,"publication_date":"2016-02-29","ids":{"openalex":"https://openalex.org/W2289934799","doi":"https://doi.org/10.1080/08897077.2015.1133472","mag":"2289934799","pmid":"https://pubmed.ncbi.nlm.nih.gov/26928397"},"language":"en","primary_location":{"id":"doi:10.1080/08897077.2015.1133472","doi":"https://doi.org/10.1080/08897077.2015.1133472","is_oa":false,"landing_page_url":"https://doi.org/10.1080/08897077.2015.1133472","pdf_url":null,"source":{"id":"https://openalex.org/S199665586","display_name":"Substance Abuse","issn_l":"0889-7077","issn":["0889-7077","1547-0164"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","norway-1","poland-70","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Substance Abuse","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2289934799"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054654890","display_name":"Raye Z. Litten","orcid":"https://orcid.org/0000-0001-7497-0809","observed_orcids":["https://orcid.org/0000-0001-7497-0809","https://orcid.org/0000-0002-5273-2989"]},"institutions":[{"id":"https://openalex.org/I4210121815","display_name":"National Institute on Alcohol Abuse and Alcoholism","ror":"https://ror.org/02jzrsm59","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210121815"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Raye Z. Litten","raw_affiliation_strings":["NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA","institution_ids":["https://openalex.org/I4210121815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056861950","display_name":"Bonnie B. Wilford","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bonnie B. Wilford","raw_affiliation_strings":["Coalition on Physician Education in Substance Use Disorders (COPE), Easton, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Coalition on Physician Education in Substance Use Disorders (COPE), Easton, Maryland, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014344861","display_name":"Daniel E. Falk","orcid":"https://orcid.org/0000-0002-3753-2786","observed_orcids":["https://orcid.org/0000-0002-3753-2786"]},"institutions":[{"id":"https://openalex.org/I4210121815","display_name":"National Institute on Alcohol Abuse and Alcoholism","ror":"https://ror.org/02jzrsm59","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210121815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel E. Falk","raw_affiliation_strings":["NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA","institution_ids":["https://openalex.org/I4210121815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103825432","display_name":"Megan L. Ryan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121815","display_name":"National Institute on Alcohol Abuse and Alcoholism","ror":"https://ror.org/02jzrsm59","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210121815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Megan L. Ryan","raw_affiliation_strings":["NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA","institution_ids":["https://openalex.org/I4210121815"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001823672","display_name":"Joanne B. Fertig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121815","display_name":"National Institute on Alcohol Abuse and Alcoholism","ror":"https://ror.org/02jzrsm59","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210121815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanne B. Fertig","raw_affiliation_strings":["NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NIAAA's Clinical Investigations Group (NCIG), Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA","institution_ids":["https://openalex.org/I4210121815"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5054654890"],"corresponding_institution_ids":["https://openalex.org/I4210121815"],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":null,"fwci":1.6525,"has_fulltext":false,"cited_by_count":100,"citation_normalized_percentile":{"value":0.85947047,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"37","issue":"2","first_page":"286","last_page":"298"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11207","display_name":"Alcohol Consumption and Health Effects","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alcoholism","display_name":"alcoholism","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.8700000047683716},{"id":"https://openalex.org/keywords/disulfiram","display_name":"disulfiram","score":0.9390000104904175},{"id":"https://openalex.org/keywords/naltrexone","display_name":"naltrexone","score":1.0},{"id":"https://openalex.org/keywords/acamprosate","display_name":"acamprosate","score":1.0},{"id":"https://openalex.org/keywords/nalmefene","display_name":"nalmefene","score":0.9580000042915344},{"id":"https://openalex.org/keywords/varenicline","display_name":"varenicline","score":0.9919999837875366},{"id":"https://openalex.org/keywords/gabapentin","display_name":"gabapentin","score":0.9559999704360962},{"id":"https://openalex.org/keywords/topiramate","display_name":"topiramate","score":0.9990000128746033},{"id":"https://openalex.org/keywords/zonisamide","display_name":"zonisamide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/baclofen","display_name":"baclofen","score":1.0},{"id":"https://openalex.org/keywords/ondansetron","display_name":"ondansetron","score":0.9980000257492065},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.9980000257492065},{"id":"https://openalex.org/keywords/serotonin-reuptake-inhibitors","display_name":"serotonin reuptake inhibitors","score":0.9760000109672546},{"id":"https://openalex.org/keywords/off-label-drug-use","display_name":"off-label drug use","score":0.8180000185966492},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.5450000166893005},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.9459999799728394},{"id":"https://openalex.org/keywords/personalized-medicine","display_name":"personalized medicine","score":0.8999999761581421}],"concepts":[{"id":"https://openalex.org/C2779992327","wikidata":"https://www.wikidata.org/wiki/Q337668","display_name":"Acamprosate","level":5,"score":0.9143673181533813},{"id":"https://openalex.org/C2778523461","wikidata":"https://www.wikidata.org/wiki/Q409665","display_name":"Disulfiram","level":2,"score":0.7785954475402832},{"id":"https://openalex.org/C2779442783","wikidata":"https://www.wikidata.org/wiki/Q15326","display_name":"Alcohol use disorder","level":3,"score":0.7625910639762878},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7370687127113342},{"id":"https://openalex.org/C2777683783","wikidata":"https://www.wikidata.org/wiki/Q221174","display_name":"Topiramate","level":3,"score":0.7086512446403503},{"id":"https://openalex.org/C2777053506","wikidata":"https://www.wikidata.org/wiki/Q411330","display_name":"Varenicline","level":3,"score":0.6685307621955872},{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.6449755430221558},{"id":"https://openalex.org/C2777972943","wikidata":"https://www.wikidata.org/wiki/Q409587","display_name":"Naltrexone","level":4,"score":0.618358314037323},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.5827299356460571},{"id":"https://openalex.org/C2777138316","wikidata":"https://www.wikidata.org/wiki/Q219957","display_name":"Zonisamide","level":4,"score":0.571327805519104},{"id":"https://openalex.org/C2778836221","wikidata":"https://www.wikidata.org/wiki/Q4353252","display_name":"Nalmefene","level":5,"score":0.5560975670814514},{"id":"https://openalex.org/C2776608144","wikidata":"https://www.wikidata.org/wiki/Q410352","display_name":"Gabapentin","level":3,"score":0.5207278728485107},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5147912502288818},{"id":"https://openalex.org/C188313352","wikidata":"https://www.wikidata.org/wiki/Q119697","display_name":"Off-label use","level":2,"score":0.4526826739311218},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3387618958950043},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2839561104774475},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.13510048389434814},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.135053813457489},{"id":"https://openalex.org/C2781066024","wikidata":"https://www.wikidata.org/wiki/Q156","display_name":"Alcohol","level":2,"score":0.13460242748260498},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.1109132170677185},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1079045832157135},{"id":"https://openalex.org/C2779547902","wikidata":"https://www.wikidata.org/wiki/Q28086552","display_name":"Nicotine","level":2,"score":0.09407752752304077},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.09012529253959656},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077443","descriptor_name":"Acamprosate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000427","descriptor_name":"Alcohol Deterrents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004221","descriptor_name":"Disulfiram","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011619","descriptor_name":"Psychotropic Drugs","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013654","descriptor_name":"Taurine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013654","descriptor_name":"Taurine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019973","descriptor_name":"Alcohol-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D056687","descriptor_name":"Off-Label Use","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/08897077.2015.1133472","doi":"https://doi.org/10.1080/08897077.2015.1133472","is_oa":false,"landing_page_url":"https://doi.org/10.1080/08897077.2015.1133472","pdf_url":null,"source":{"id":"https://openalex.org/S199665586","display_name":"Substance Abuse","issn_l":"0889-7077","issn":["0889-7077","1547-0164"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","norway-1","poland-70","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Substance Abuse","raw_type":"journal-article"},{"id":"pmid:26928397","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26928397","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Substance abuse","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320306127","display_name":"U.S. Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98"},{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":93,"referenced_works":["https://openalex.org/W215685540","https://openalex.org/W1531379989","https://openalex.org/W1924646378","https://openalex.org/W1965829294","https://openalex.org/W1965938052","https://openalex.org/W1967507587","https://openalex.org/W1970051522","https://openalex.org/W1974160618","https://openalex.org/W1979794009","https://openalex.org/W1985556674","https://openalex.org/W1987065152","https://openalex.org/W1991280516","https://openalex.org/W1993563487","https://openalex.org/W1997348850","https://openalex.org/W1999116765","https://openalex.org/W2000431953","https://openalex.org/W2000904449","https://openalex.org/W2003711874","https://openalex.org/W2006833508","https://openalex.org/W2015006945","https://openalex.org/W2016691339","https://openalex.org/W2020972628","https://openalex.org/W2022064715","https://openalex.org/W2022672407","https://openalex.org/W2024799025","https://openalex.org/W2026704544","https://openalex.org/W2031654719","https://openalex.org/W2032552670","https://openalex.org/W2032749582","https://openalex.org/W2032849758","https://openalex.org/W2035839366","https://openalex.org/W2037144736","https://openalex.org/W2037311654","https://openalex.org/W2040126205","https://openalex.org/W2042340338","https://openalex.org/W2044336844","https://openalex.org/W2044777166","https://openalex.org/W2046964321","https://openalex.org/W2048975472","https://openalex.org/W2050247926","https://openalex.org/W2050505630","https://openalex.org/W2051244114","https://openalex.org/W2052729611","https://openalex.org/W2063907389","https://openalex.org/W2064832878","https://openalex.org/W2064910054","https://openalex.org/W2069850786","https://openalex.org/W2073314272","https://openalex.org/W2074170871","https://openalex.org/W2075663070","https://openalex.org/W2076390838","https://openalex.org/W2078594409","https://openalex.org/W2082206299","https://openalex.org/W2084115967","https://openalex.org/W2088265204","https://openalex.org/W2091377765","https://openalex.org/W2093986666","https://openalex.org/W2100886729","https://openalex.org/W2101039973","https://openalex.org/W2104086074","https://openalex.org/W2105355442","https://openalex.org/W2105726924","https://openalex.org/W2106405930","https://openalex.org/W2107687266","https://openalex.org/W2108740579","https://openalex.org/W2110504918","https://openalex.org/W2113673166","https://openalex.org/W2115581910","https://openalex.org/W2119106378","https://openalex.org/W2122807925","https://openalex.org/W2123475692","https://openalex.org/W2123841796","https://openalex.org/W2125199618","https://openalex.org/W2125230596","https://openalex.org/W2126709720","https://openalex.org/W2136006910","https://openalex.org/W2136475835","https://openalex.org/W2141246891","https://openalex.org/W2141859631","https://openalex.org/W2143344901","https://openalex.org/W2145176659","https://openalex.org/W2149660440","https://openalex.org/W2150602253","https://openalex.org/W2153465183","https://openalex.org/W2158878763","https://openalex.org/W2159274748","https://openalex.org/W2159492208","https://openalex.org/W2160792252","https://openalex.org/W2167514365","https://openalex.org/W2170057342","https://openalex.org/W2172137255","https://openalex.org/W2334516706","https://openalex.org/W2417560069"],"related_works":["https://openalex.org/W4387917608","https://openalex.org/W4280626209","https://openalex.org/W2986662798","https://openalex.org/W2732821476","https://openalex.org/W4410779110","https://openalex.org/W4210944481","https://openalex.org/W2952666020","https://openalex.org/W2782063084","https://openalex.org/W4377965564","https://openalex.org/W3118363993"],"abstract_inverted_index":{"Alcohol":[0,245],"use":[1],"disorder":[2,19],"(AUD),":[3],"as":[4,121],"currently":[5],"defined":[6],"in":[7,137,151,207],"the":[8,50,93,144,147,241,252,263],"Diagnostic":[9],"and":[10,28,67,79,96,106,184,222,247,254,259,268,271,277],"Statistical":[11],"Manual,":[12],"5th":[13],"Edition":[14],"(DSM-5),":[15],"is":[16,38,76],"a":[17,22,32,60,73,122,124,235],"heterogeneous":[18],"stemming":[20],"from":[21,219],"complex":[23],"interaction":[24],"of":[25,34,62,126,135,149,190,256,265],"neurobiological,":[26],"genetic,":[27],"environmental":[29],"factors.":[30],"As":[31],"result":[33],"this":[35,164],"heterogeneity,":[36],"there":[37],"no":[39],"one":[40],"treatment":[41,134,148],"for":[42,47,133,146,163,240],"AUD":[43,136],"that":[44,75,202],"will":[45],"work":[46],"everyone.":[48],"During":[49],"past":[51],"2":[52],"decades,":[53],"efforts":[54],"have":[55,89,115,210],"been":[56,90,194],"made":[57],"to":[58,64,100,110,205,274],"develop":[59],"menu":[61],"medications":[63,88,128,156,168,192],"give":[65],"patients":[66],"clinicians":[68,162],"more":[69,257,278],"choices":[70],"when":[71],"seeking":[72],"therapy":[74],"both":[77],"effective":[78,258,279],"which":[80],"has":[81,193],"limited":[82],"side":[83,200],"effects.":[84],"To":[85],"date,":[86],"3":[87],"approved":[91,112,142],"by":[92,143,161],"US":[94],"Food":[95],"Drug":[97],"Administration":[98],"(FDA)":[99],"treat":[101],"alcohol":[102],"dependence:":[103],"disulfiram,":[104],"naltrexone,":[105],"acamprosate.":[107],"In":[108],"addition":[109],"these":[111,154,191],"medications,":[113,261],"researchers":[114],"identified":[116],"new":[117,276],"therapeutic":[118],"targets":[119],"and,":[120],"result,":[123],"number":[125],"alternative":[127,155],"are":[129,157,169,203,216],"now":[130],"being":[131,158],"evaluated":[132],"human":[138],"studies.":[139],"Although":[140],"not":[141],"FDA":[145],"AUD,":[150],"some":[152],"cases,":[153],"used":[159],"off-label":[160],"purpose.":[165],"These":[166],"potential":[167],"reviewed":[170],"here.":[171],"They":[172],"include":[173,250],"nalmefene,":[174],"varenicline,":[175],"gabapentin,":[176],"topiramate,":[177],"zonisamide,":[178],"baclofen,":[179],"ondansetron,":[180],"levetiracetam,":[181],"quetiapine,":[182],"aripiprazole,":[183],"serotonin":[185],"reuptake":[186],"inhibitors.":[187],"The":[188],"effectiveness":[189],"mixed-some":[195],"show":[196,225],"good":[197],"efficacy":[198],"with":[199],"effects":[201],"mild":[204],"moderate":[206],"intensity;":[208],"others":[209,224],"mixed":[211],"or":[212],"promising":[213,229],"results":[214],"but":[215],"awaiting":[217],"findings":[218],"ongoing":[220],"studies;":[221],"still":[223],"poor":[226],"efficacy,":[227],"despite":[228],"preliminary":[230],"results.":[231],"Medications":[232],"development":[233,255],"remains":[234],"high":[236],"priority.":[237],"Key":[238],"initiatives":[239],"National":[242],"Institute":[243],"on":[244],"Abuse":[246],"Alcoholism":[248],"(NIAAA)":[249],"supporting":[251],"discovery":[253],"safer":[260],"advancing":[262],"field":[264],"personalized":[266],"medicine,":[267],"forging":[269],"public":[270],"private":[272],"partnerships":[273],"investigate":[275],"compounds.":[280]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2289934799","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":15},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":3}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
